Background: Integrated palliative care (IPC) is regarded as the standard therapy for advanced cancer. We conduct a comprehensive analysis to evaluate current evidence for the effectiveness of IPC on quality of life (QoL) and psychological distress among patients with advanced cancer. Differences in effectiveness are explored regarding various types of IPC and the follow-up time/period.
Methods: A systematic literature search of PubMed, PsycINFO, EMBASE, CINAHL, and Cochrane Central Register of Controlled Trials was conducted. We identified 12 randomized controlled trials, which included 2,356 participants, that were pooled using a random-effects meta-analysis.
Results: Our results suggested no significant difference between the three different models of IPC and conventional treatment on overall QoL (SMD =0.06, 95% CI: -0.06 to 0.17, P=0.318). However, there was a long-lasting favorable effect of IPC on overall QoL throughout the follow-up period of 12 to 18 weeks (SMD =0.13, 95% CI: 0.02 to 0.24, P=0.016). The inpatient consulting model was more effective than other models in reducing depression and anxiety symptoms (SMD =-0.42, 95% CI: -0.64 to -0.19, P<0.001; SMD =-0.31, 95% CI: -0.54 to -0.09, P=0.006). In the early period of approximately 2 weeks of follow-up, IPC was shown to be significantly more effective in reducing depression and anxiety symptoms (SMD =-0.30, 95% CI: -0.52 to -0.07, P=0.009; SMD =-0.45, 95% CI: -0.68 to -0.23, P<0.001). IPC was also effective in decreasing posttraumatic stress disorder (PTSD) symptoms (SMD =-0.46, 95% CI: -0.69 to -0.23, P<0.001).
Conclusions: IPC can effectively improve QoL and alleviate early psychological distress in patients with advanced cancer. The inpatient consulting model of IPC was more effective than other models in reducing depression and anxiety symptoms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.21037/apm-22-162 | DOI Listing |
iScience
January 2025
Department of Adult Health Nursing, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Comprehensive data on the epidemiology of cancer-related thrombosis in Africa has been sparse until recently. Thus, this review was aimed to investigate the magnitude of cancer-related thrombosis in Africa. To obtain key articles, comprehensive search was conducted using various databases.
View Article and Find Full Text PDFiScience
January 2025
School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao 266113, China.
Cell-cell interactions and communication represent the fundamental cornerstone of cells' collaborative efforts in executing diverse biological processes. A profound understanding of how cells interface through various mediators is pivotal across a spectrum of biological systems. Recent strides in microfluidic technologies have significantly bolstered the precision and prowess in capturing and manipulating cells with exceptional spatial and temporal resolution.
View Article and Find Full Text PDFJ Surg Case Rep
January 2025
Department of Pathology of the National Institute of Oncology, Ibn Sina University Hospital Center, Allal Al Fassi Avenue, Rabat 10100, Morocco.
Mesonephric-like adenocarcinoma (MLA) is a rare and newly recognized subtype of ovarian and endometrial carcinomas, introduced in the 2020 World Health Organization Classification. This tumor likely originates from Müllerian-derived tissues and often mimics more common ovarian cancers, leading to frequent misdiagnosis. This case study details a 36-year-old woman who presented with urinary symptoms following a hysterectomy.
View Article and Find Full Text PDFFront Med (Lausanne)
January 2025
Department Three of Orthopedics/Plastic Surgery, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, China.
Objective: This study systematically evaluated the efficacy of programmed death 1 (PD-1) inhibitors combined with chemotherapy for advanced esophageal cancer (EC).
Methods: PubMed, Embase, Web of Science, Scopus, and Cochrane Library were searched to identify related randomized controlled trials (RCTs).
Results: Seven RCTs involving 4,363 participants were included.
Front Immunol
January 2025
Department of Neuro-oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Introduction: Glioma is the most common primary malignant brain tumor. Despite advances in surgical techniques and treatment regimens, the therapeutic effects of glioma remain unsatisfactory. Immunotherapy has brought new hope to glioma patients, but its therapeutic outcomes are limited by the immunosuppressive nature of the tumor microenvironment (TME).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!